Regulatory actions, compounding rules, and clinical-trial readouts — explained in plain English, with what each update does and doesn’t mean.
Every item here links to primary reporting and describes what was actually announced. We flag what is reported versus confirmed, and none of it is medical advice. Dates reflect when we published the explainer.
What the compounding list is, what could change on it, and what patients should watch as policy updates break.
A high-level explainer of the reported Phase 3 topline for retatrutide — what a “topline” readout is, and what it does not yet establish.
The FDA signaled action against mass-marketed, non-FDA-approved GLP-1 drugs. What the statement does and doesn’t mean, and what to ask your clinician or pharmacy.
The April 2026 shortage-status update and the compounding fallout it triggers — plus a simple checklist for tracking refills and next steps.
What an FDA warning letter is, what it does and doesn’t mean for the companies named, and how to keep your own orders and paperwork organized.
A higher-dose Wegovy was reported approved under the National Priority Voucher program. An educational overview of what the approval covers.
Lower-cost semaglutide is reported to be launching in India after key patent expiries — and how to sanity-check prices, strengths, and brand confusion.
What “impurity” claims about compounded tirzepatide usually mean, how to read product paperwork, and what to ask your prescriber or pharmacy.
What was reported about Hims & Hers stepping back from a compounded oral-semaglutide plan, and what it likely means for availability and marketing wording.
A plain-English look at the Zealand/Roche amylin Phase 2 readout and the market reaction — and what an early-stage readout can and can’t tell you.
Following the GLP-1 and peptide space? Track your own doses privately and honestly. Jabbit is an ad-free injection log — no data selling, no hype.
Download on App Store